How (APGE) Movements Inform Risk Allocation Models
The article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE) using AI models, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It presents various trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles. The analysis details support and resistance levels across multiple timeframes, providing risk-reward ratios for potential trades.
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales
Apogee Therapeutics (APGE) reported widening net losses in Q1 2026 but saw its developmental inflammation therapy meet trial objectives. Despite this clinical success, which has kept Wall Street analysts positive, the company faces typical early-stage biotech risks such as widening losses, insider share sales, and ongoing financing needs. The article suggests focusing on future Phase 2 and Phase 3 milestones while being aware of potential shareholder dilution and financing risks.
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales
Apogee Therapeutics (APGE) reported widening Q1 2026 net losses of US$74.11 million, but its developmental inflammation therapy recently met trial objectives. Wall Street analysts maintain positive views following the trial success, despite ongoing losses and insider share sales, which highlight the typical risks associated with early-stage biotech. The company's future catalysts include upcoming Phase 2 and 3 milestones, while financing risk and dilution remain concerns due to cash burn and follow-on offerings.
How Investors Are Reacting To Apogee Therapeutics (APGE) Trial Win Amid Wider Losses And Insider Sales
Apogee Therapeutics (APGE) reported wider Q1 2026 net losses of US$74.11 million, but its developmental inflammation therapy recently met trial objectives. Wall Street analysts maintain positive views on Apogee due to its trial success, despite insider share sales and increasing losses reflecting typical early-stage biotech risks and funding needs. Investors must consider the company's reliance on new capital and potential for dilution, as well as the upcoming Phase 2 and 3 milestones for its lead candidate, zumilokibart.
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock By Investing.com
Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of company stock for a total of $1.64 million on May 13, 2026, as part of a pre-established trading plan. The sale occurred while Apogee shares have nearly doubled over the past year, though InvestingPro suggests the stock may be overvalued. Despite this insider sale, analysts from Jefferies, Mizuho, BTIG, and Rothschild Redburn have expressed positive sentiment, raising price targets and initiating Buy ratings due to the company's successful stock offering and promising therapeutic pipeline, particularly for atopic dermatitis.
Apogee Therapeutics CEO Michael Henderson sells $1.64m in stock
Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of company stock for a total of $1.64 million on May 13, 2026, through a pre-established trading plan. Following the sale, Henderson directly holds over 1.1 million shares. This comes amidst analyst optimism and a recent successful stock offering by Apogee, despite the stock trading below its 52-week high.
Apogee Therapeutics (APGE) CEO sells 20,000 shares under 10b5-1 plan
Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares of common stock on May 13, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The sales occurred at weighted average prices of approximately $82.05 and $82.58 per share. Despite these transactions, Henderson retains over one million shares of Apogee Therapeutics.
Apogee Therapeutics, Inc. - Common Stock (NQ: APGE)
This article provides recent news headlines for Apogee Therapeutics, Inc. (APGE) stock, including its performance and news related to its IPO and clinical trial outcomes. Key updates highlight the company's developmental inflammation treatment success and general discussions about biotech stocks.
Jefferies raises Apogee Therapeutics stock price target on trial outlook
Jefferies has increased its price target for Apogee Therapeutics Inc. (NASDAQ: APGE) to $120 from $100, maintaining a Buy rating, based on the outlook for the company's Phase 2 APEX Part B atopic dermatitis data expected in Q2 2026. The firm projects high-dose zumi treatment to show a placebo-adjusted EASI-75 of 45-50% and raised its risk-adjusted peak sales estimate for zumi monotherapy to $2.5 billion. Other analysts have also reiterated positive ratings and price targets for Apogee, following a recent public offering and clinical data presentations.
Jefferies raises Apogee Therapeutics stock price target on trial outlook By Investing.com
Jefferies has increased its price target for Apogee Therapeutics (NASDAQ: APGE) to $120 from $100, maintaining a Buy rating, ahead of anticipated Phase 2 atopic dermatitis trial data in Q2 2026. The firm expects strong results for the zumi treatment, projecting high-dose zumi to show placebo-adjusted EASI-75 of 45-50%, contributing to an raised risk-adjusted peak sales estimate for zumi monotherapy to $2.5 billion. Other analysts also initiated or reiterated buy ratings, reflecting ongoing interest in Apogee's financial and clinical progress, despite InvestingPro's fair value analysis suggesting the stock may be overvalued.
Jefferies raises Apogee Therapeutics stock price target on trial outlook
Jefferies has increased its price target for Apogee Therapeutics (NASDAQ:APGE) to $120 from $100, maintaining a Buy rating, based on optimistic trial outlooks. The firm anticipates positive Phase 2 APEX Part B atopic dermatitis data in Q2 2026 and has raised its risk-adjusted peak sales estimate for zumi monotherapy to $2.5 billion. Apogee Therapeutics also recently completed a public offering raising approximately $403 million, and has received positive analyst coverage from Rothschild Redburn, BTIG, and Mizuho.
APGE (APGE) Form 144: Insider-related sale notices, 60,000 shares planned
Apogee Therapeutics (APGE) has filed a Form 144, indicating a proposed resale of 60,000 shares of common stock under Rule 144. The filing also notes two recent sales of 20,000 shares each by Michael Henderson on March 11, 2026, and April 8, 2026, with reported gross proceeds. As of May 13, 2026, the company has 75,389,375 shares outstanding.
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Apogee Therapeutics announced Pipeline Progress and released its First Quarter 2026 Financial Results. This release provides an update on the company's advancements in drug development and its financial performance for the quarter, offering insights into its strategic direction and operational health.
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Apogee Therapeutics reported its first quarter 2026 financial results and provided an update on its pipeline, highlighting the advancement of zumilokibart. The company anticipates initiating Phase 3 trials for zumilokibart in atopic dermatitis later this year, following positive Phase 2 data showing durable efficacy. Apogee also announced a strong cash position of $1.3 billion, extending its financial runway into 2029 through a planned BLA filing for atopic dermatitis.
Apogee Therapeutics (NASDAQ: APGE) reports cash runway and Phase 2 AD data
Apogee Therapeutics reported a net loss of $74.1 million for Q1 2026, up from $55.3 million a year prior, primarily due to increased R&D and G&A expenses. Despite widening losses, the company maintains strong liquidity with $451.8 million in cash and equivalents and $806.5 million in marketable securities, projecting at least 12 months of operational funding. Apogee also highlighted positive Phase 2 data for its lead antibody, zumilokibart, in atopic dermatitis and provided updates on its other immunology pipeline programs.
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, Vs. FactSet Est of $74.2M
Apogee Therapeutics (APGE) reported a Q1 net loss of $74.1 million, which was slightly better than FactSet's estimated loss of $74.2 million. This earnings flash provides the headline figures for the company's first-quarter performance.
Apogee Therapeutics (Nasdaq: APGE) Q1 loss widens, cash runway to 2029
Apogee Therapeutics reported a wider net loss of $74.1 million for Q1 2026, primarily due to increased R&D and G&A spending. Despite this, the company significantly strengthened its financial position with $1.3 billion in cash, cash equivalents, and marketable securities, supported by a $403 million public equity offering, extending its cash runway into 2029. Apogee also highlighted strong 52-week Phase 2 APEX Part A data for zumilokibart in atopic dermatitis and positive interim Phase 1b asthma results, indicating progress towards planned Phase 3 trials and a future BLA filing.
Apogee Therapeutics 1Q 2026: Net loss $(74.1M), No product revenue — 10-Q Summary
Apogee Therapeutics reported a net loss of $(74.1M) for Q1 2026, widening from the previous year, with no product revenue expected for several years. Despite the financial loss, the company announced positive clinical milestones for zumilokibart and progress in its pipeline, securing funding to extend its cash runway into 2029 to support future clinical and operational plans.
Apogee's AD drug zumilokibart keeps 52-week response with 3- and 6-month dosing
Apogee Therapeutics announced Q1 2026 financial results revealing a net loss of $74.1 million but a strong cash position of $1.3 billion, extending its financial runway into 2029. The company also reported positive 52-week data for its drug zumilokibart in atopic dermatitis showing durable maintenance and improved efficacy with 3- and 6-month dosing, supporting planned Phase 3 trials in the second half of 2026. Additionally, zumilokibart showed positive interim results in a Phase 1b asthma trial, highlighting its potential across multiple inflammatory and immunology indications.
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Apogee Therapeutics announced significant pipeline progress, particularly for its drug zumilokibart, with successful Phase 2 data in atopic dermatitis (AD) showing durable efficacy and plans for Phase 3 initiation later in 2026. The company also reported strong financial results for Q1 2026, with a cash position of $1.3 billion extending its runway into 2029 following a successful public equity offering. Future plans include expanding trials for zumilokibart into asthma and eosinophilic esophagitis, and advancing combination therapies.
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $74.1M, vs. FactSet Est of $74.2M
Apogee Therapeutics (APGE) reported a Q1 net loss of $74.1 million, which is slightly better than FactSet's estimated net loss of $74.2 million. The company is a clinical-stage biotechnology firm focused on developing novel biologics for inflammatory and immunology markets. Its lead program, APG777, is being developed for atopic dermatitis.
Apogee Therapeutics Insider Sold Shares Worth $462,784, According to a Recent SEC Filing
An insider at Apogee Therapeutics has sold shares valued at $462,784, as reported in a recent SEC filing. This transaction occurred on May 11, 2026, though specific details about the insider were not provided in the snippet. Apogee Therapeutics (APGE) is a clinical-stage biotechnology company focusing on inflammatory and immunology markets.
APGE SEC Filings - Apogee Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Apogee Therapeutics (APGE) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents. Stock Titan aggregates these filings, offering insights into the company's financial activities, material events, and insider trading, supplemented with AI-powered summaries. Recent filings highlight director equity compensation and the outcomes of the 2025 Annual Meeting of Stockholders.
Apogee Therapeutics (APGE) CMO sells 5,500 shares, exercises 4,125 options
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 5,500 shares of common stock at weighted average prices of $84.60 and $83.92 per share. Concurrently, he exercised 4,125 stock options at an exercise price of $22.86 per share. These transactions, executed on May 6, 2026, were part of a pre-arranged Rule 10b5-1 trading plan adopted in September 2025.
Apogee Therapeutics CMO Dambkowski sells $462,784 in shares By Investing.com
Carl Dambkowski, CMO of Apogee Therapeutics (NASDAQ:APGE), sold common stock totaling $462,784 on May 6, 2026, after acquiring shares through the exercise of stock options for $94,297. The sales were conducted under a Rule 10b5-1 trading plan. Despite not being profitable in the past year, the company holds a "GOOD" financial health rating and has seen recent positive analyst coverage and a successful public offering.
Trading Systems Reacting to (APGE) Volatility
This article from Stock Traders Daily discusses the volatility of Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting both positive near-term sentiment and a mid-term weak bias within a long-term strong outlook. It presents AI-generated trading strategies including a position trading strategy, a momentum breakout strategy, and a risk-hedging strategy, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes an exceptional risk-reward short setup for APGE.
Insider to sell 22,000 shares at APGE (NASDAQ: APGE) after 11,000 sold
An insider at Apogee Therapeutics, Inc. (NASDAQ: APGE) has filed to sell 22,000 common shares, comprising 16,500 from exercised stock options and 5,500 from restricted stock awards. This filing also reveals two previous 10b5-1 sales totaling 11,000 shares in March and April 2026, generating over $857,000. These transactions are detailed in a Form 144 SEC filing.
Should Zumilokibart’s Phase 2 Data and Insider Sales Activity Require Action From Apogee Therapeutics (APGE) Investors?
Apogee Therapeutics recently announced promising Phase 2 data for its drug candidate zumilokibart, alongside new bullish analyst coverage, which highlights the potential for infrequent dosing. While insider sales by Jane Henderson are noted, the article suggests they are modest and unlikely to alter the company’s core risk profile. The investment narrative hinges on zumilokibart's commercial viability and the company's ability to fund operations despite ongoing losses, with significant potential for dilution.
CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan
Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold a total of 2,000 shares of the company's common stock on May 1, 2026. These sales were executed in three separate transactions at weighted average prices between approximately $81 and $83 per share, as part of a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. Following these transactions, Henderson directly holds 173,371 shares of Apogee common stock.
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation
Rothschild & Co has initiated coverage of Apogee Therapeutics (APGE) with a "buy" recommendation. This suggests a positive outlook from the investment bank regarding the pharmaceutical company's future stock performance.
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Apogee Therapeutics (NASDAQ:APGE) to a "strong-buy" rating, contributing to a MarketBeat consensus of "Moderate Buy" with an average price target of $112.73. Despite recent insider selling, institutional investors have increased their holdings, and the company has a market capitalization of $4.99 billion. Apogee Therapeutics is a clinical-stage biotechnology company focusing on treatments for inflammatory skin disorders.
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE
Jennison Associates LLC acquired a new position in Apogee Therapeutics Inc. (NASDAQ:APGE) worth $43.68 million in the fourth quarter, purchasing 578,627 shares. Analyst sentiment for APGE is largely positive with a "Moderate Buy" consensus and a target price of $112.73, despite some insider selling. The company, a clinical-stage biotechnology firm, focuses on developing treatments for inflammatory skin disorders.
Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades
Apogee Therapeutics (NASDAQ: APGE) insider Jane Henderson reported five separate 2,000-share sales of common stock under a 10b5-1 trading plan. These transactions occurred on February 2, March 2, March 25, April 1, and April 16, 2026, with individual gross proceeds ranging from $131,622.00 to $180,000.00. The sales relate to a Restricted Stock Award granted on February 1, 2023.
Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140
Rothschild & Co Redburn has initiated coverage on Apogee Therapeutics (APGE.US) with a Buy rating. The firm has set a target price of $140 for Apogee Therapeutics. This move suggests a positive outlook on the company's future performance by the analyst firm.
Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE
Pictet Asset Management Holding SA has acquired a new stake of 312,883 shares in Apogee Therapeutics Inc. (NASDAQ:APGE), valued at approximately $23.62 million. This move is consistent with various institutional investors adjusting their holdings in the company. Despite recent insider selling, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $110.79.
Rothschild Redburn initiates Apogee stock with buy on AD therapy
Rothschild Redburn initiated coverage on Apogee Therapeutics (NASDAQ:APGE) with a buy rating and a $140 price target, citing the company's lead asset, APG777, for atopic dermatitis, expected to launch in 2029. The firm forecasts a significant market opportunity and profitability by 2032, despite current overvaluation according to InvestingPro. This initiation follows recent successful public offerings and positive analyst adjustments, highlighting strong investor interest in Apogee's pipeline.
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation
Rothschild & Co has initiated coverage of Apogee Therapeutics (APGE) with a "buy" recommendation. This suggests a positive outlook from the investment firm regarding the company's future performance.
Apogee Therapeutics (APGE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Apogee Therapeutics presented positive Phase II data for atopic dermatitis, showing rapid itch relief and significant lesion improvement, with expectations for extended dosing intervals. Their Phase 1b asthma study demonstrated notable FeNO reduction and durable effects, supporting quarterly dosing and market expansion into asthma. The company plans for a 2029 launch, aiming to challenge current market leaders with a strong cash runway and optimized manufacturing.
Apogee Therapeutics (APGE) Study result Summary
Apogee Therapeutics announced positive 52-week results from their Phase II APEX Part A study for zumilokibart in adults with moderate-to-severe atopic dermatitis. The study demonstrated maintained and deepening efficacy with every 3- or 6-month dosing, showing high EASI-75 and IGA 0/1 response rates. Zumilokibart also exhibited a well-tolerated safety profile consistent with the IL-13 class, with mostly mild adverse events like non-infective conjunctivitis.
Apogee Therapeutics Stock Surges as Investors Bet on Immunology Breakthrough
Apogee Therapeutics (NASDAQ:APGE) stock is surging as investors are betting on its lead drug candidate, Zumilokibart, following positive Phase 2 clinical data. The drug, which offers extended dosing intervals of every three or six months, is seen as a disruptive force against established bi-weekly treatments. The company recently raised $403 million through a public offering, securing its financial runway through 2028 and enabling it to fund Phase 3 trials and further development without shareholder dilution.
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis
Apogee Therapeutics shares increased significantly after announcing positive interim results from its global Phase 2 study of zumilokibart (APG777) for moderate-to-severe atopic dermatitis. The data indicated that all three doses of zumilokibart met the primary efficacy endpoint with high rates of Eczema Area and Severity Index (EASI) improvements and favorable safety. This news positions Apogee to potentially advance zumilokibart as a best-in-class treatment for atopic dermatitis.
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing
This article analyzes Apogee Therapeutics Inc. (APGE) for rotational strategy timing, noting weak near-term sentiment but strong mid and long-term outlooks. It highlights an exceptional risk-reward setup with a target gain of 15.1% against 0.3% risk. The analysis provides three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders on APGE.
Two directors resign from Apogee Therapeutics (NASDAQ: APGE) board, shrinking it to seven
Apogee Therapeutics (NASDAQ: APGE) announced that two directors, Andrew Gottesdiener, M.D., and Peter Harwin, will resign from its Board of Directors effective May 11, 2026. This move will reduce the board's size from nine to seven members. The company clarified that these resignations are not due to any disagreements regarding its operations, policies, or practices.
Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026.
Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are under a lock-up agreement set to expire on April 24, 2026. This lock-up period began on March 24, 2026, lasting 31 days. The agreement prevents company executives, directors, and director-affiliated funds from selling or offering to sell any securities without prior consent from Jefferies LLC.
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026.
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a lock-up agreement ending on April 24, 2026. These units will be locked up for 31 days, from March 24, 2026, to April 24, 2026. This restriction applies to the company, executive officers, directors, and director-affiliated funds, preventing them from selling or offering to sell securities without prior written consent from Jefferies LLC.
Certain Common Stock of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026.
Certain common shares of Apogee Therapeutics, Inc. are under a lock-up agreement, preventing their sale, offer, or similar transactions from March 24, 2026, to April 24, 2026. This restriction applies to the company, executive officers, directors, and director-affiliated funds. The lock-up period is either 30 or 60 days, depending on the role, and aims to maintain market stability after a prospectus supplement.
Apogee Therapeutics (APGE) CEO exercises options, holds 1.14M shares
Apogee Therapeutics CEO Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock at $22.86 per share, increasing his direct holdings to 1,135,987 shares. These options were part of a larger grant of 398,512 shares that vest over four years, with 387,012 options from this grant remaining outstanding and set to expire in December 2033. This transaction was reported in a Form 4 SEC filing.
Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan
Apogee Therapeutics, Inc.'s CFO, Jane Henderson, sold 2,000 shares of common stock at $90.00 per share on April 16, 2026, totaling $180,000. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 2, 2025. After the sale, Henderson directly holds 175,371 shares of Apogee common stock.
Apogee Therapeutics CFO Henderson sells $180,000 in stock
Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock for $180,000, executed under a pre-arranged trading plan, while the stock trades near its 52-week high. The company recently completed a public offering raising $403 million and announced another public offering for $350 million. Analysts BTIG and Mizuho have reiterated positive ratings and raised price targets for Apogee Therapeutics following recent data presentations.
Apogee Therapeutics stock hits all-time high at 92.48 USD
Apogee Therapeutics Inc. has seen its stock reach an all-time high of $92.48, resulting in a market capitalization of $6.6 billion and a 173.48% increase over the past year. Despite this surge and strong investor confidence, InvestingPro data suggests the stock may be overvalued, trading near its 52-week high and in overbought territory. The company recently completed a stock offering raising approximately $403 million, and analysts like BTIG and Mizuho have reiterated Buy and Outperform ratings respectively, with increased price targets.
